Tacrolimus
Listing ID#148879
ModelCAS: 104987-11-3
CategoryChemicals

Tacrolimus

Specifications

Brand
YC
Origin
Hubei China
Certifications
ISO9001
MOQ
5Kg
Packaging
As your request
Price Term
FOB CIF
Payment Term
T/T,WesternUnion,Moneygram
Supply Ability
4500Kg/Month
Delivery Time
4-6 working days
Loading Ports
Shenzhen Hongkong Shanghai
Guarantee
ISO9001
Request Quote
Quick answer

Tacrolimus is a Chemicals product. Key specs — Brand: YC; Origin: Hubei China; Certifications: ISO9001; MOQ: 5Kg.

Product Description

Product Name: Tacrolimus Synonyms: (2-propenyl)-,(3s-(3r*(e(1s*,3s*,4s*)),4s*,5r*,8s*,9e,12r*,14r*,15s*,16r*,18s*;,19s*,26ar*))-;16-dimethoxy-4,10,12,18-tetramethyl-8-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1;19-epoxy-3h-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4h,23h)-tetrone,5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-14,16-dim;6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-5;fr900506;prograf;tsukubaenolide CAS: 104987-11-3 MF: C44H69NO12 MW: 804.02 Product Categories: Active Pharmaceutical Ingredients;Immunosuppressant.;Intermediates & Fine Chemicals;Pharmaceuticals;API;Chiral Reagents;Fujimycin, Prograf;antibiotic mp 113-115°C storage temp. ?20°C solubility DMSO: >3 mg/mL form solid color white Chemical Properties White Crystalline Solid Usage An immunosuppressant that blocks T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially IL-2.

Shown to inhibit the activity of FK-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum Ca+2 release.

Usage FK-506 (Tacrolimus) is a macrolide immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system Usage Tacrolimus (fujimycin) was discovered as a potent inhibitor of IL2 production in a targeted search for novel immunosuppressants.

Tacrolimus acts by blocking T cell proliferation in vitro by inhibiting the generation of several lymphokines, notably the original target IL-2. Tacrolimus inhibits the activity of FK-506 binding protein, Ca2+-dependent phosphatase and calcineurin, and activates NF-κB through phosphorylation and degradation of IκBα.

Usage treatment of Cushing's syndrome Usage For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart.

Related Products